The Economic Implications of Treating Atherothrombotic Disease in Australia, From the Government Perspective
Zanfina Ademi, Danny Liew, Bruce Hollingsworth, Rory Wolfe, Gabriel P Steg, Deepak L Bhatt, Christopher M Reid
Clinical Therapeutics | ELSEVIER | Published : 2010
BACKGROUND: The management of atherothrombotic disease is responsible for a large proportion of direct medical costs in most countries, imposing a substantial financial burden on health care payers. There is limited knowledge about direct per-person medical costs using a "bottom-up" approach. OBJECTIVE: This study was designed to estimate the per-person direct medical costs incurred by communitybased subjects in Australia who have or are at high risk for atherothrombotic disease. The perspective was a governmental one, at the federal level for pharmaceuticals and at the state level for hospitalizations. METHODS: One-year follow-up data were obtained for Australian participants in the interna..View full abstract
Awarded by Australian Research Council
This work was supported by Monash University. It was also supported In part by the Australian Research Council Linkage Project LP077532.